A subunit vaccine for the treatment of seasonal and pandemic flu

Recombinant subunit vaccines are based on the expression of the main antigenic protein of the target virus and do not use the flu virus or chicken eggs in the manufacturing process. This allows high expression levels and improves vaccine safety.

Cilian’s CiFlu influenza vaccine is a quadrivalent protein subunit vaccine produced using an egg- and virus-free, recombinant DNA platform. It produces an exact genetic match to the target antigen hemagglutinin (HA) of both A and B strains of influenza viruses.

CiFlu has shown high and complete inhibitory immunogenicity in vivo, which means complete protection against the virus. Due to its high efficacy, the CiFlu subunit vaccine can be used, if desired, without adjuvants and is compatible with any desired adjuvant.

Reference: Jawinski K et al. Recombinant Haemagglutinin Derived From the Ciliated Protozoan Tetrahymena thermophila Is Protective Against Influenza Infection. Front Immunol. 2019